Ovitrel - instructions for use, reviews, analogs and forms of release (injections in ampoules for hypodermic injections 250 mcg 6500 IU) of a drug for the treatment of female infertility, stimulation of ovulation and the onset of pregnancy in women. Composition

In this article, you can read the instructions for using the drug Ovitrel. Presented are reviews of visitors to the site - consumers of this medication, as well as the opinions of doctors of specialists on the use of Ovitrel in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Ovitrel with available structural analogues.Use for the treatment of female infertility, stimulation of ovulation and the onset of pregnancy in women. Composition of the preparation.

Ovitrel - recombinant chorioradotropin alfa, which has the same amino acid sequence as the natural human chorionic gonadotropin. It binds the transmembrane LH receptors on the surface of the cells of the teki and granulosa of the ovary. Causes initiation of oocyte meiosis, rupture of follicles (ovulation), formation of a yellow body, production of Progesterone and estradiol by a yellow body.

Composition

Choriogonadotropin alfa (hCG-alpha) + auxiliary substances.

Pharmacokinetics

With subcutaneous administration, the absolute bioavailability is approximately 40%.

Indications

• in the protocol of induction of multiple follicular maturation (superovulation) for auxiliary reproductive technologies (including for in vitro fertilization or IVF) with the aim of inducing the final maturation of follicles and luteinization after stimulation with gonadotropins;
• with anovulatory or oligo-ovulatory infertility for induction of ovulation and luteinization at the end of stimulation of follicle growth.

Forms of release

Solution for subcutaneous administration of 250 mcg (6500 IU) (injections in ampoules or syringes for injection).

Lyophilizate for the preparation of a solution for subcutaneous administration (in vials).

Other dosage forms, be it tablets or capsules, do not exist.

Instructions for use and dosing regimen

The drug is administered subcutaneously. Each syringe is for single use only.

When applied in the induction protocol for the multiple maturation of follicles for assisted reproductive technologies (including for in vitro fertilization) to induce the final maturation of follicles and luteinization after stimulation with gonadotropins, Ovitrel 250 μg (the contents of 1 syringe) is administered once through 24-48 h after the last injection of FSH or LH and the optimal level of development of the follicle.

With anovulatory or oligovulatory infertility for induction of ovulation and luteinization at the end of stimulation of the growth of follicles, Ovitrel in a dose of 250 μg (the contents of 1 syringe) is injected once 24-48 hours after reaching the optimal level of development of the follicle. It is recommended to have sexual intercourse on the day of drug administration and the next day.

Rules of drug administration

When self-administered, patients should carefully read the instructions.

1. Injection should be carried out in accordance with the rules of asepsis and antiseptics.
2. To carry out the injection, it is necessary to spread out on a clean surface 2 alcohol impregnated swabs, a pre-filled syringe or a ready-to-use syringe.
3. Next, you should immediately inject (in the abdomen or the front of the thigh). To do this, wipe selected by the recommendation of the doctor site with a swab with alcohol. Strongly pull the skin with your fingers and, by directing the needle at an angle of 45-90 degrees in the skin fold, make a subcutaneous injection. It is necessary to avoid getting the drug into the vein. The drug is injected slowly, gently pressing the plunger, it is necessary to enter the entire volume of the solution. After removing the needle, wipe the place of injection with a swab with alcohol in a circular motion.
4. Immediately after the injection, the used syringe should be placed in a container for storing sharp objects. All unused volume should be destroyed.

In the case of an increased dose of the drug or a missed injection, the patient should consult a doctor.

Side effect

• nausea, vomiting;
• abdominal pain;
• diarrhea;
• ovarian hyperstimulation syndrome (OCS);
• OCS severe;
• tenderness of the mammary glands;
• headache;
• depression;
• irritability;
• anxiety;
• fatigue;
• reversible mild skin rash;
• pain and hyperemia at the injection site;
• feeling tired;
• allergic reactions in mild form.

Contraindications

• tumors in the hypothalamus and pituitary;
• voluminous ovarian neoplasms or cysts not associated with polycystic ovary;
• vaginal bleeding of unknown origin;
• cancer of the ovary, uterus or breast;
• ectopic pregnancy within 3 previous months;
• thromboembolism;
• primary ovarian failure;
• congenital malformations of the reproductive organs incompatible with pregnancy;
• uterine fibroids, incompatible with pregnancy;
• postmenopause;
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Not noted.

Use in children

Not used.

special instructions

Before the beginning of treatment it is necessary to establish the causes of infertility in the patient and her partner and to evaluate the expected risk factors for the onset of pregnancy.It should take into account the presence of clinically pronounced hypothyroidism, adrenal insufficiency, hyperprolactinaemia, the presence of tumors of the pituitary and hypothalamus, the specific methods of therapy used.

In the process of stimulation of the ovaries, the patients are at risk of developing the hyperstimulation syndrome (HSV) due to the simultaneous ripening of a large number of follicles. In clinical trials of OHSS (in most cases, mild to moderate), approximately 4% of patients were observed. A severe hypoglycemic episode can be a serious complication of stimulation. In rare cases, the complication of severe SWC may be hemoperitoneum, acute respiratory distress syndrome, ovarian torsion and thromboembolism. In order to reduce the risk of hypoglycemia in the protocol for stimulating the growth of follicles, careful monitoring of ovarian response with ultrasound and the determination of the level of estradiol in the blood before and during the course of treatment are recommended.

In comparison with natural fertilization, the risk of multiple pregnancy increases during stimulation. In most cases, twins are born.When using methods of assisted reproduction, the number of babies born corresponds to the number of embryos transferred to the uterine cavity.

With caution, Ovitrel should be prescribed to patients with serious systemic diseases in those cases where pregnancy can lead to their exacerbation.

Statistics of miscarriages after treatment of anovulatory infertility (including assisted reproductive technologies) exceed the average for the population, but comparable to other types of infertility.

The introduction of Ovitrel can influence the immunological picture of the hCG level in serum and urine for 10 days and lead to a false positive reaction in the pregnancy test.

During the treatment with Ovitrel, slight stimulation of thyroid function is possible.

Patients should be warned about the need to report to the doctor about the increase in side effects or about side effects not described above.

Within the expiry date, storage of the drug outside the refrigerator is allowed at a temperature of no higher than 25 degrees Celsius for 30 days. The drug should be destroyed if it is not used during this period.

Impact on the ability to drive vehicles and manage mechanisms

Ovitril does not affect the ability to drive vehicles and work with mechanisms.

Drug Interactions

Until now, there is no data on interactions with other drugs.

The patient should inform the doctor about all medications (including over-the-counter drugs) that she is currently or recently taking.

Analogues of the drug Ovitrel

Structural analogues for the active substance of the drug Ovitrel does not.

Analogues on the curative effect (funds for the treatment of female infertility and preparation for IVF):

• Agalates;
• Bromocriptine Richter;
• Buserelin;
• Buserelin depot;
• Gonal F;
• Decapeptil;
• Decapeptil depot;
• Dostineks;
• Zoladex;
• Infukol GEC;
• Clostilbite;
• Krajonon;
• Menogon;
• Menopur;
• Pergoveris;
• Pureghon;
• Utrozhestan;
• Cetrotid;
• Elonva.

Similar medicines:

Other medicines: